Evidence map›Paper›PMID 36412593›Full record

ArticleDiseases (Basel, Switzerland)2022

Association of Alleles of Human Leukocyte Antigen Class II Genes and Severity of COVID-19 in Patients of the 'Red Zone' of the Endocrinology Research Center, Moscow, Russia.

Ekaterina Troshina, Marina Yukina, Nurana Nuralieva, Evgeny Vasilyev, Olga Rebrova, Ravida Akhmatova, Anna Ikonnikova, Elena Savvateeva, Dmitry Gryadunov, Galina Melnichenko and 1 more

Open access · goldAbstract read
In one paragraph

Article in Diseases (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. COVID-19: Where We Are and Where We Are Going.Diseases (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Ekaterina TroshinaEndocrinology Research Centre, Ministry of Health of the Russian Federation, 117036 Moscow, Russia.
Marina YukinaEndocrinology Research Centre, Ministry of Health of the Russian Federation, 117036 Moscow, Russia.ORCID 0000-0002-8771-8300
Nurana NuralievaEndocrinology Research Centre, Ministry of Health of the Russian Federation, 117036 Moscow, Russia.ORCID 0000-0001-6876-3336
Evgeny VasilyevEndocrinology Research Centre, Ministry of Health of the Russian Federation, 117036 Moscow, Russia.
Olga RebrovaEndocrinology Research Centre, Ministry of Health of the Russian Federation, 117036 Moscow, Russia.
Ravida AkhmatovaEndocrinology Research Centre, Ministry of Health of the Russian Federation, 117036 Moscow, Russia.
Anna IkonnikovaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.ORCID 0000-0002-8434-5916
Elena SavvateevaCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.ORCID 0000-0003-3091-8245
Dmitry GryadunovCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.ORCID 0000-0003-3183-318X
Galina MelnichenkoEndocrinology Research Centre, Ministry of Health of the Russian Federation, 117036 Moscow, Russia.
Natalia MokryshevaEndocrinology Research Centre, Ministry of Health of the Russian Federation, 117036 Moscow, Russia.
Ministry of Health of the Russian Federation · RUEngelhardt Institute of Molecular Biology · RU

Funding

Foundation for Scientific and Technological Development of Yugra 2022-05-01/2022
6 · The paper itself

Abstract

The aim of this study was to assess the correlations of clinical features of patients with moderate and severe courses of COVID-19, comorbidity (endocrine, autoimmune, cardiovascular, oncological, and pulmonary diseases), and alleles of the HLA class II system genes. One hundred COVID-19 patients hospitalized in the Endocrinology Research Centre, Moscow, Russia, were analyzed for age, gender, smoking, comorbidity, and invasive mechanical ventilation. Computer tomography was used to assess the severity of the disease. HLA-DRB1, HLA-DQA1, and HLA-DQB1 alleles were identified in samples from 100 patients and samples from 327 randomly selected individuals collected in the prepandemic period (control group). There was no association of gender, age, weight, body mass index, smoking, and comorbidity with the severity of COVID-19. Allele DQB1*06:02-8 was more common in patients (p < 0.00005), and DQB1*06:01 and DQB1*05:03 were more common in the control group (p < 0.00005, and p = 0.0011, respectively). DQB1*06:02-8 can probably be considered as predisposing to moderate and severe COVID-19, and DQB1*06:01 can be considered as protective. No association of these alleles with comorbidity was found. Our results suggest that carriers of predisposing alleles, with cardiovascular and non-autoimmune endocrine diseases, should take more stringent preventive measures, and if infected, a more aggressive COVID-19 treatment strategy should be used.

Indexed as

clinical featurescomorbidityCOVID-19HLA class II genesseverity of disease

Identifiers

PMID36412593
PMCPMC9680278
OpenAlexW4309213955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.